On April 21, 2025, the launch conference and the first technical guidance committee of the "Shijiazhuang Precision Prevention and Control Technology Innovation Center for Birth Defects" of Hebei Reproductive and Obstetrics Hospital were successfully held at the hospital. At the meeting, Hebei Reproductive Obstetrics and Gynecology Hospital hired Professor Huang Yihua, founding scientist and chairman of Polyseq Biotechnology, as a research expert consultant for Shijiazhuang Leren Health Medical Laboratory and Shijiazhuang Birth Defects Precision Prevention and Control Technology Innovation Center, providing strategic support for their technological innovation. Professor Deng Kai, Director of the Department of Genetics and Innovation Center at Hebei Reproductive and Obstetrics Hospital, signed a scientific research strategic cooperation agreement with Beijing Polyseq Biotechnology Co., Ltd. on behalf of Shijiazhuang Leren Health Medical Laboratory, Shijiazhuang Precision Birth Defects Prevention and Control Technology Innovation Center. Based on the concept of complementary advantages in technology and resources, Polyseq Biotechnology will assist the Innovation Center and Medical Laboratory in developing projects and products in the fields of assisted reproduction and prenatal diagnosis using Polyseq nanopore sequencers.
signing ceremony
Left: Professor Deng Kai; Right: Professor Huang Yihua
At the meeting, relevant leaders, experts, and scholars expressed their high recognition of the universal translation of biological nanopore sequencing technology and products. Professor Cai Liyi, the director of Hebei Reproductive and Obstetrics Hospital, has made it clear that the hospital will continue to invest in this research to ensure its smooth progress and establish characteristic projects within the hospital. Experts such as Dr. Shen Yiping from the Department of Neurology at Harvard Medical School, Dr. Wang Shusong from the Science and Technology Committee of Hebei Reproductive Hospital, and genetic medicine consultant at Hebei Reproductive and Obstetrics Hospital, have expressed high expectations for the collaboration between this technology and clinical practice, as well as for the integration of medicine and engineering and precision innovation.
(Professor Shen Yiping)
(Professor Cai Liyi)
Director Deng Kai also presented the preliminary data achievements obtained since the cooperation between the two parties in the report, emphasizing the breakthrough progress and enormous application value of nanopore sequencing in assisted reproductive testing. This technology not only significantly improves detection accuracy and efficiency, but also provides a more accurate and reliable basis for clinical diagnosis.
Huang Yihua, Chairman of Polyseq Biotechnology, also reported to the attending leaders and experts at the meeting on the latest progress of the company's 99% accuracy sequencing chemistry and high-throughput chips, and revealed that the relevant results will be released in the middle of the year. He stated that with the continuous advancement of technology, faster and higher accuracy detection will be achieved in the future.
As the construction unit of Shijiazhuang Precision Prevention and Control Technology Innovation Center for Birth Defects, Hebei Reproductive and Obstetrics Hospital has the qualification to carry out assisted reproductive technology embryo genetic testing and prenatal sample genetic testing. The center is committed to improving the three-level prevention system for pre pregnancy, pre pregnancy, and birth defects, covering fields such as reproductive medicine, embryonic genetics, and precision prevention and control. Its aim is to nip genetic problems in the embryonic stage and provide comprehensive genomic testing services for pre pregnancy, pre pregnancy, and birth defects. The Technology Innovation Center will also conduct in-depth exploration in three directions: clinical research, technology transformation, and social services.
The successful holding of this conference not only demonstrates the professional strength of Hebei Reproductive and Obstetrics Hospital in the field of birth defect prevention and control, but also marks the official launch of its cooperation with Polyseq Biotechnology in scientific research. Both sides will rely on their respective advantages to jointly promote the innovative development of birth defect prevention and control technology, and make greater contributions to the maternal and child health cause in Hebei Province and even the whole country.
